Swedish-based CDMO Recipharm announced at CPHI that it is “expanding its pharmaceutical development capabilities through targeted investments and the integration of cutting-edge technologies”. This, it said, will bolster services at both early- and late- stage development, giving it fully integrated services that cover the whole life cycle of a molecule. These additions comprise:

Blue Wolf Capital Partners, a US-based private equity firm, has agreed to acquire seven Recipharm sites from EQT Private Equity, subject to regulatory approval in a deal that should close in Q4. These are located at Solna, Strängnäs, Höganäs, Karlskoga and Uppsala in Sweden; Pessac, France; and Parets, Spain.

The board of Swedish-based CDMO Recipharm has unanimously recommended that shareholders accept a revised offer for the firm from Roar BidCo, a vehicle set up by investment organisation EQT IX and backed by chairman Lars Backsell and CEO Thomas Eldered. The offer period ends on 12 February. Roar BidCo has said that it does not plan any changes to the management team or for employees.

Several of the world’s major pharmaceutical CDMOS have recently made announcements relating to their participation in projects to develop treatment for the Covid-19 virus. Many involve chloroquines, in anticipation of their large-scale use.